Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Petra Pharma Corporation

Request full access

Drug development company focused on therapies for serious medical conditions such as cancer and metabolic diseases

New York City, United StatesFounded 2016Biotech & Life Sciences

About Petra Pharma Corporation

Petra Pharma Corporation operates as a biopharmaceutical firm focused on developing treatments for cancer and metabolic diseases by targeting key cellular processes. The company was established in 2016 and originated from the work of its co-founders, Dr. Lewis Cantley and Dr. Nathanael Gray. It was launched by the life science investment and management firm, Accelerator Corporation, and headquartered in New York City.

Dr. Lewis Cantley is a cell biologist and biochemist recognized for his discovery of the phosphoinositide 3-kinase (PI3K) signaling pathway, which is crucial in understanding cancer and diabetes. His extensive research into how these biochemical pathways regulate cell growth and can lead to cancer when defective forms the scientific bedrock of Petra Pharma. Co-founder Dr. Nathanael Gray is a chemist with a background in organic chemistry and has held significant roles at Harvard Medical School and the Dana-Farber Cancer Institute. His expertise lies in discovering and validating new strategies for inhibiting anti-cancer targets. The synergy between Cantley's deep understanding of cancer metabolism and Gray's proficiency in drug discovery chemistry provided a strong foundation for the company.

The company's primary business involves the development of small molecule inhibitors that target novel enzymes central to cellular functions like cell division, growth, and signaling. By modulating these phosphoinositide (PI) signaling pathways, Petra aims to create new therapeutic options for patients. The business model is centered on advancing its scientific discoveries through preclinical and clinical development, funded by significant venture capital investment. The company secured a notable $48 million in a Series A financing round at its launch, with investors including major pharmaceutical companies like AbbVie, Eli Lilly and Company, and Pfizer Venture Investments. Total funding reached $75.5 million over two rounds. In 2022, Petra Pharma was acquired by Eli Lilly.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
54.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
DEBTDebt Apr 2020 $28M — Undisclosed —
SPINOUT✓Other financing Jan 2016 $0 — Harvard University —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Petra Pharma Corporation website traffic

Latest recorded traffic for Petra Pharma Corporation is 140 monthly website visits, down 39.1% over the last three months.

Latest monthly visits140 3-month web change-39.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Petra Pharma Corporation in the New York City ecosystem

Live from Dealroom

The Petra Pharma Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Pfizer Ventures

Other known investors2 additional known investors

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · New York City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Petra Pharma Corporation on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Petra Pharma Corporation’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.